Skip to main content
Caplight Logo









DermBiont

DermBiont

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.dermbiont.com/

Last Round

Series B

Oct 24, 2023

Total Funding Raised

$76.65M

Company Overview

DermBiont is a biotechnology company that develops targeted topical therapeutics for rare disease oncology and aesthetic dermatology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologytopical therapeuticsdermatologydrug discoveryclinical trialssmall molecule inhibitorshyperpigmentation treatmentbasal cell carcinomabiotech startupclinical stagemelasma treatmenttopical drug deliverytherapeutic pipelineskin disease researchpharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DermBiont Comparables

Compare DermBiont with similar companies based on industry and business-model similarity.

DermBiont comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PellePharm
88%
NFlection Therapeutics
84%
AOBiome Therapeutics Inc.
78%

DermBiont Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 24, 2023
DebtMar 28, 2023
Series A ExtensionDec 21, 2021
Series AJun 18, 2019
AcceleratorApr 26, 2018

Key People

Founding team and executive leadership

Max Dawson

Chief Operating Officer

Executive Team

DermBiont Investors

Notable investors and investment history

DermBiont investors
InvestorRounds
Viking Global InvestorsSeries B, Series A Extension, Series A
Toba CapitalSeries A Extension, Series A
Zola GlobalSeries A
Pivotal bioVenture PartnersSeries A Extension
Civilization VenturesSeries B, Series A Extension
Double Point VenturesSeries B
Illumina AcceleratorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 22, 2026

    Monthly visitors increased 44% MoM, reaching 1.3K.

  • Dec 21, 2021

    $28M round led by Pivotal bioVenture Partners.

DermBiont Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

DermBiont Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about DermBiont's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range14
Year Founded2017
Last FundingOct 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?